Adoption and use of immunotherapy in breast cancer management in Africa: barriers and prospect – a narrative review

Abstract

Breast cancer (BC) is the world’s most frequently diagnosed cancer in women, with 7.8 million women diagnosed with breast cancer in the past five years. BC has the highest incidence rate of all cancers in women worldwide (1.67 million), accounting for over 500,000 deaths annually. In Africa, breast cancer accounts for 28% of all cancer and 20% of all cancer deaths in women. The African continent has recorded an alarming increase in incidence, with the highest mortality rate globally. Despite BC being a major health concern in Africa, there is limited access to adequate healthcare services to combat the growing need. Immunotherapy, a promising treatment approach that harnesses the immune system’s power to fight cancer, has shown great potential in breast cancer management. However, in the face of the growing body of evidence supporting its effectiveness, the adoption and use of immunotherapy in breast cancer management in Africa remain limited. Hence, this review aimed to explore the barriers and prospects of immunotherapy adoption and use in breast cancer management in Africa. A comprehensive search across various databases and sources using specific keywords related to immunotherapy and breast cancer to achieve the study aim was conducted. The criteria for including data in the study were based on relevance and availability in English, with no publication year restrictions. The collected data underwent narrative analysis, supplemented by information from sources like country reports, newsletters, commentaries, policy briefs, and direct Google searches. By identifying the challenges and opportunities, this review provided insights into how healthcare providers, policymakers, and other stakeholders can work together to improve the availability and accessibility of immunotherapy to breast cancer patients in Africa.